Literature DB >> 9833140

Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs.

J Weirich1, H Antoni.   

Abstract

Rate or frequency-dependence is a characteristic property of antiarrhythmic drugs belonging to the Vaughan William classes I and III. The rate-dependence of class I drugs (i.e., increasing blockade of fast Na(+)-channels with faster rates) results from periodical drug binding to Na(+)-channel sites which are preferably available in the activated and/or inactivated channel states (use-dependence). With respect to their binding and unbinding kinetics, class I drugs can be subdivided into three groups (group 1-group 3) which differ in their block-frequency relations as well as in their onset kinetics of channel blockade. These properties can serve as predictors of the anti- and proarrhythmic potential of class I drugs. Class III drugs (blockers of potassium channels) are mostly characterized by reverse rate-dependence (loss of class III action at faster rates). However, this property cannot be attributed to reverse use-dependence, i.e., binding to channels in the rested state. It is more likely due to different rate-dependent contributions of the two components of the delayed rectifier potassium current to repolarization, when the rapidly activating, the rectifying component IKr is specifically blocked by class III drugs, while the slowly activating component IKs remains unchanged. In spite of their reverse rate-dependence, class III drugs exert an antifibrillatory effect when fibrillation is induced by frequent stimulation. This can be attributed to the slow time course of the decline (offset kinetics) of the class III effect accompanying a sudden increase in frequency. Proarrhythmic effects of class III drugs result from the delay in repolarization that may favor the development of early afterdepolarizations. The proarrhythmic potential of class III drugs is species dependent and is favored if the contribution of IKr to the repolarization phase of the action potential is comparatively large.

Mesh:

Substances:

Year:  1998        PMID: 9833140     DOI: 10.1007/s003950050236

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  10 in total

1.  Blocking effect of methylflavonolamine on human Na(V)1.5 channels expressed in Xenopus laevis oocytes and on sodium currents in rabbit ventricular myocytes.

Authors:  Xin-rong Fan; Ji-hua Ma; Pei-hua Zhang; Jun-lian Xing
Journal:  Acta Pharmacol Sin       Date:  2010-02-22       Impact factor: 6.150

2.  In silico assessment of drug safety in human heart applied to late sodium current blockers.

Authors:  Beatriz Trenor; Julio Gomis-Tena; Karen Cardona; Lucia Romero; Sridharan Rajamani; Luiz Belardinelli; Wayne R Giles; Javier Saiz
Journal:  Channels (Austin)       Date:  2013 Jul-Aug       Impact factor: 2.581

3.  In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.

Authors:  Franco Borsini; William Crumb; Silvia Pace; David Ubben; Barb Wible; Gan-Xin Yan; Christian Funck-Brentano
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 4.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206

5.  Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L).

Authors:  Torsten Christ; Erich Wettwer; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-06-16       Impact factor: 3.000

6.  Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent.

Authors:  Jeffry Shearer; Gary Wolfe; Aruna Sampath; Kelly L Warfield; Brian Kaufman; Urban Ramstedt; Anthony Treston
Journal:  Int J Toxicol       Date:  2022-02-28       Impact factor: 2.380

7.  Management of Chloroquine and Hydroxychloroquine Poisoning: Do Not Miss the Time of Tracheal Intubation and Mechanical Ventilation.

Authors:  Bruno Megarbane; Azzurra Schicchi
Journal:  West J Emerg Med       Date:  2021-01-11

8.  Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.

Authors:  Aziza El Harchi; Dario Melgari; Yi Hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.

Authors:  Yuji Haraguchi; Atsushi Ohtsuki; Takayuki Oka; Tatsuya Shimizu
Journal:  BMC Pharmacol Toxicol       Date:  2015-12-16       Impact factor: 2.483

10.  Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen.

Authors:  Laurent M A Favié; Alwin D R Huitema; Marcel P H van den Broek; Carin M A Rademaker; Timo R de Haan; Henrica L M van Straaten; Sinno H P Simons; Monique Rijken; Debbie H G M Nuytemans; Toine C G Egberts; Floris Groenendaal
Journal:  Br J Clin Pharmacol       Date:  2020-01-03       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.